- Immunotherapies developer for the treatment of cancer Scancell Holdings booked a deeper full-year loss as it continued to develop its main drug candidates.

Pre-tax losses for the year through April amounted to £6.7m, compared to losses of £4.9m on-year.

The company recently announced that it would kick off a new clinical trail in the UK, but had withdrawn a request to start the same trial in the US following approval delays.

'We have made strong progress this year in advancing our pipeline of novel immunotherapies,' chief executive Cliff Holloway said.

'Importantly, post period, we were pleased to initiate the UK arm of the SCIB1 Phase 2 trial, whilst disappointed with the need to withdraw our IND application to achieve this.'

'We intend to resubmit the IND at the earliest opportunity.'

Story provided by